Login Register Cart 0
Generic placeholder image

Mini-Reviews in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-193X
ISSN (Online): 1875-6298

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Overview of the Synthesis of Pyrazolotriazolopyrimidine Compounds

Author(s): Jin Luo*, Puqing Chen and Chonghu Song

Volume 17, Issue 6, 2020

Page: [674 - 685] Pages: 12

DOI: 10.2174/1570193X16666190723124839

Price: $65

Abstract

Pyrazolotriazolopyrimidines are an important class of nitrogen-containing heterocycles that can act as a charismatic target and exhibit diverse pharmacological activities. These compounds have received much attention because they are an attractive scaffold for the preparation of adenosine receptor antagonists. Herein, we focus on an overview of the synthesis of these compounds with the aim of assisting in the discovery of new pyrazolotriazolopyrimidine derivatives.

Keywords: Adenosine receptor antagonists, nitrogen-containing heterocycles, attractive scaffold, pharmacological activities, pyrazolotriazolopyrimidines, synthesis.

« Previous Next »
Graphical Abstract

[1]
Luo, J.; Zhao, A.L.; Zheng, C.H.; Wang, T. Synthesis and herbicidal activity of novel 6-arylthio-3-methylthio-1 H-pyrazolo [3, 4-d] pyrimidin-4 (5 H)-ones. Phosphorus Sulfur Silicon Relat. Elem., 2017, 192(10), 1124-1126.
[http://dx.doi.org/10.1080/10426507.2017.1333508]
[2]
Wang, H.Q.; Zhou, W.P.; Wang, Y.Y.; Lin, C.R. Synthesis and antifungal activities of novel 5-amino-6-arylamino-1Hpyrazolo[3,4-d]pyrimidin-4(5H)-one derivatives. J. Agric. Food Chem., 2008, 56(16), 7321-7325.
[http://dx.doi.org/10.1021/jf801359f] [PMID: 18672885]
[3]
Russo, F.; Guccione, S.; Romeo, G.; Monsu’Scolaro, L.; Pucci, S.; Caruso, A.; Roxas, M.A. Synthesis and pharmacological properties of pyrazolotriazolo pyrimidine derivatives. Eur. J. Med. Chem., 1992, 27(1), 73-80.
[http://dx.doi.org/10.1016/0223-5234(92)90064-8]
[4]
Tageldin, G.N.; Ibrahim, T.M.; Fahmy, S.M.; Ashour, H.M.; Khalil, M.A.; Nassra, R.A.; Labouta, I.M. Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents. Bioorg. Chem., 2019. 90102844
[http://dx.doi.org/10.1016/j.bioorg.2019.03.018] [PMID: 31229797]
[5]
Nagamatsu, T.; Fujita, T. Facile and general syntheses of 3-and/or 5-substituted 7 H-pyrazolo[4, 3-e]-1, 2, 4-triazolo[4, 3-c] pyrimidines as a new class of potential xanthine oxidase inhibitors. Chem. Commun., 1999, 16, 1461-1462.
[http://dx.doi.org/10.1039/a903676h]
[6]
Abunada, N.M.; Hassaneen, H.M.; Kandile, N.G.; Miqdad, O.A. Synthesis and antimicrobial activity of some new pyrazole, fused pyrazolo[3,4-d]-pyrimidine and pyrazolo[4,3-e][1,2,4]-triazolo[1,5-c]pyrimidine derivatives. Molecules, 2008, 13(7), 1501-1517.
[http://dx.doi.org/10.3390/molecules13071501] [PMID: 18719521]
[7]
Romdhane, A.; Said, A.B.; Cherif, M.; Jannet, H.B. Design, synthesis and anti-acetylcholinesterase evaluation of some new pyrazolo [4, 3-e]-1, 2, 4-triazolo [1, 5-c] pyrimidine derivatives. Med. Chem. Res., 2016, 25(7), 1358-1368.
[http://dx.doi.org/10.1007/s00044-016-1576-0]
[8]
El Yacoubi, M.; Ledent, C.; Parmentier, M.; Bertorelli, R.; Ongini, E.; Costentin, J.; Vaugeois, J.M. Adenosine A2A receptor antagonists are potential antidepressants: Evidence based on pharmacology and A2A receptor knockout mice. Br. J. Pharmacol., 2001, 134(1), 68-77.
[http://dx.doi.org/10.1038/sj.bjp.0704240] [PMID: 11522598]
[9]
Melani, A.; Dettori, I.; Corti, F.; Cellai, L.; Pedata, F. Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia. Neurol. Sci., 2015, 36(8), 1441-1448.
[http://dx.doi.org/10.1007/s10072-015-2160-y] [PMID: 25805704]
[10]
Ali, H.I.; Fujita, T.; Akaho, E.; Nagamatsu, T. A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors. J. Comput. Aided Mol. Des., 2010, 24(1), 57-75.
[http://dx.doi.org/10.1007/s10822-009-9314-z] [PMID: 20039101]
[11]
Baraldi, P.G.; Fruttarolo, F.; Tabrizi, M.A.; Preti, D.; Romagnoli, R.; El-Kashef, H.; Moorman, A.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. J. Med. Chem., 2003, 46(7), 1229-1241.
[http://dx.doi.org/10.1021/jm021023m] [PMID: 12646033]
[12]
Yang, Z.J.; Wang, B.; Kwansa, H.; Heitmiller, K.D.; Hong, G.; Carter, E.L.; Jamrogowicz, J.L.; Larson, A.C.; Martin, L.J.; Koehler, R.C. Adenosine A2A receptor contributes to ischemic brain damage in newborn piglet. J. Cereb. Blood Flow Metab., 2013, 33(10), 1612-1620.
[http://dx.doi.org/10.1038/jcbfm.2013.117] [PMID: 23860373]
[13]
Viana da Silva, S.; Haberl, M.G.; Zhang, P.; Bethge, P.; Lemos, C.; Gonçalves, N.; Gorlewicz, A.; Malezieux, M.; Gonçalves, F.Q.; Grosjean, N.; Blanchet, C.; Frick, A.; Nägerl, U.V.; Cunha, R.A.; Mulle, C. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer’s disease involve neuronal adenosine A2A receptors. Nat. Commun., 2016, 7, 11915.
[http://dx.doi.org/10.1038/ncomms11915] [PMID: 27312972]
[14]
Baraldi, P.G.; Cacciari, B.; Moro, S.; Spalluto, G.; Pastorin, G.; Da Ros, T.; Klotz, K.N.; Varani, K.; Gessi, S.; Borea, P.A. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. J. Med. Chem., 2002, 45(4), 770-780.
[http://dx.doi.org/10.1021/jm0109614] [PMID: 11831890]
[15]
Pinto-Duarte, A.; Coelho, J.E.; Cunha, R.A.; Ribeiro, J.A.; Sebastião, A.M. Adenosine A2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus. J. Neurochem., 2005, 93(3), 595-604.
[http://dx.doi.org/10.1111/j.1471-4159.2005.03071.x] [PMID: 15836618]
[16]
Pastorin, G.; Da Ros, T.; Spalluto, G.; Deflorian, F.; Moro, S.; Cacciari, B.; Baraldi, P.G.; Gessi, S.; Varani, K.; Borea, P.A. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: A molecular modeling investigation. J. Med. Chem., 2003, 46(20), 4287-4296.
[http://dx.doi.org/10.1021/jm030852k] [PMID: 13678407]
[17]
Cacciari, B.; Bolcato, C.; Spalluto, G.; Klotz, K.N.; Bacilieri, M.; Deflorian, F.; Moro, S. Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile. Purinergic Signal., 2007, 3(3), 183-193.
[http://dx.doi.org/10.1007/s11302-006-9027-x] [PMID: 18404432]
[18]
Lauria, A.; Abbate, I.; Patella, C.; Gambino, N.; Silvestri, A.; Barone, G.; Almerico, A.M. Pyrazolo [3, 4-d][1, 2, 3]triazolo[1, 5-a] pyrimidine: A new ring system through Dimroth rearrangement. Tetrahedron Lett., 2008, 49(35), 5125-5128.
[http://dx.doi.org/10.1016/j.tetlet.2008.06.104]
[19]
Baraldi, P.G.; Saponaro, G.; Romagnoli, R.; Aghazadeh Tabrizi, M.; Baraldi, S.; Moorman, A.R.; Cosconati, S.; Di Maro, S.; Marinelli, L.; Gessi, S.; Merighi, S.; Varani, K.; Borea, P.A.; Preti, D. Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. J. Med. Chem., 2012, 55(11), 5380-5390.
[http://dx.doi.org/10.1021/jm300323t] [PMID: 22568637]
[20]
Hauser, R.; Stocchi, F.; Rascol, O.; Huyck, S.; Ha, X.; Capece, R.; Wolski, K.; Ho, T.; Sklar, P.; Lines, C.; Michelson, D.; Hewitt, D. phase-3 clinical trials of adjunctive therapy with preladenant, an adenosine 2a antagonist, in patients with parkinson’s disease (p7.087). neurology, 2014, 82(suppl.), p7.087.
[21]
Stocchi, F.; Rascol, O.; Hauser, R.; Huyck, S.; Tzontcheva, A.; Capece, R.; Wolski, K.; Ho, T.; Sklar, P.; Lines, C.; Michelson, D.; Hewitt, D. Phase-3 clinical trial of the adenosine 2a antagonist preladenant, given as monotherapy, in patients with Parkinson’s disease (S7.004). Neurology, 2014, 82(Suppl.), S7.004.
[22]
Gatta, F.; Del Giudice, M.R.; Borioni, A.; Borea, P.A.; Dionisotti, S.; Ongini, E. Synthesis of imidazo[1, 2- c]pyrazolo[4, 3-e] pyrimidines, pyrazolo [4, 3-e] 1, 2, 4-triazolo[1, 5-c] pyrimidines and 1, 2, 4-triazolo [5, 1-i] purines: New potent adenosine A2 receptor antagonists. Eur. J. Med. Chem., 1993, 28(7-8), 569-576.
[http://dx.doi.org/10.1016/0223-5234(93)90087-U]
[23]
Baraldi, P.G.; Cacciari, B.; Spalluto, G. ; Pineda de las Infantas y Villatoro, M.J.; Zocchi, C.; Dionisotti, S.; Ongini, E. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A(2A) adenosine antagonists. J. Med. Chem., 1996, 39(5), 1164-1171.
[http://dx.doi.org/10.1021/jm950746l] [PMID: 8676354]
[24]
Baraldi, P.G.; Cacciari, B.; Dionisotti, S.; Egan, J.; Spalluto, G.; Zocchi, C. Synthesis of the tritium labeled SCH 58261, a new nonxanthine A2A adenosine receptor antagonist. J. Labelled. Compd. Rad., 1996, 38(8), 725-732.
[25]
Baraldi, P.G.; Cacciari, B.; Spalluto, G.; Bergonzoni, M.; Dionisotti, S.; Ongini, E.; Varani, K.; Borea, P.A. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. J. Med. Chem., 1998, 41(12), 2126-2133.
[http://dx.doi.org/10.1021/jm9708689] [PMID: 9622554]
[26]
Baraldi, P.G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Klotz, K.N.; Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. J. Med. Chem., 1999, 42(22), 4473-4478.
[http://dx.doi.org/10.1021/jm991114s] [PMID: 10579811]
[27]
Baraldi, P.G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Moro, S.; Klotz, K.N.; Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: Influence of the chain at the N(8) pyrazole nitrogen. J. Med. Chem., 2000, 43(25), 4768-4780.
[http://dx.doi.org/10.1021/jm001047y] [PMID: 11123985]
[28]
Baraldi, P.G.; Cacciari, B.; Moro, S.; Romagnoli, R. ; Ji Xd; Jacobson, K.A.; Gessi, S.; Borea, P.A.; Spalluto, G. Fluorosulfonyl and bis-(β-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: Irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. J. Med. Chem., 2001, 44(17), 2735-2742.
[http://dx.doi.org/10.1021/jm010818a] [PMID: 11495585]
[29]
Baraldi, P.G.; Tabrizi, M.A.; Romagnoli, R.; Fruttarolo, F.; Merighi, S.; Varani, K.; Gessi, S.; Borea, P.A. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines. Curr. Med. Chem., 2005, 12(11), 1319-1329.
[http://dx.doi.org/10.2174/0929867054020963] [PMID: 15974999]
[30]
Moro, S.; Braiuca, P.; Deflorian, F.; Ferrari, C.; Pastorin, G.; Cacciari, B.; Baraldi, P.G.; Varani, K.; Borea, P.A.; Spalluto, G. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study. J. Med. Chem., 2005, 48(1), 152-162.
[http://dx.doi.org/10.1021/jm049662f] [PMID: 15634009]
[31]
Baraldi, P.G.; Baraldi, S.; Saponaro, G.; Aghazadeh Tabrizi, M.; Romagnoli, R.; Ruggiero, E.; Vincenzi, F.; Borea, P.A.; Varani, K.; Varani, K. One-pot reaction to obtain N,N′-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists. J. Med. Chem., 2015, 58(13), 5355-5360.
[http://dx.doi.org/10.1021/acs.jmedchem.5b00551] [PMID: 26046697]
[32]
Xiao, L.X.; Li, K.; Meng, L.; Shi, D.Q. A convenient synthesis of novel 7-phosphonylbenzyl-2-substituted pyrazolo[4,3-e]-1, 2, 4-triazolo[1,5-c]-pyrimidine derivatives. Heteroatom Chem., 2008, 19(6), 634-638.
[http://dx.doi.org/10.1002/hc.20478]
[33]
Fayed, A.A.; Al-Harbi, N.O.; Amr, A.E.G.E.; Kalmoush, A.A.; Shadid, K.A.; Flefel, E.M. Synthesis, reactions, and pharmacological evaluations of some novel pyridazolopyridiazine candidates. J. Het. Chem., 2014, 51(6), 1770-1777.
[http://dx.doi.org/10.1002/jhet.1881]
[34]
Federico, S.; Redenti, S.; Sturlese, M.; Ciancetta, A.; Kachler, S.; Klotz, K.N.; Cacciari, B.; Moro, S.; Spalluto, G. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4] triazolo[1,5-c]pyrimidine derivatives. PLoS One, 2015, 10(12)e0143504
[http://dx.doi.org/10.1371/journal.pone.0143504] [PMID: 26625265]
[35]
Rashad, A.E.; Shamroukh, A.H.; Abdel-Megeid, R.E.; Ali, H.S. Synthesis and isomerization of some novel pyrazolopyrimidine and pyrazolotriazolopyrimidine derivatives. Molecules, 2014, 19(5), 5459-5469.
[http://dx.doi.org/10.3390/molecules19055459] [PMID: 24776812]
[36]
Seifi, N.; Zahedi-Niaki, M.H.; Barzegari, M.R.; Davoodnia, A.; Zhiani, R.; Kaju, A.A. Synthesis of 8-aryl-1H-pyrazolo[4, 3-e][1, 2, 4] triazolo [4, 3-a] pyrimidine-4 (5H)-imine by using the Preyssler’s anion [NaP5W30O110] 14- as a green and eco-friendly catalyst. J. Mol. Catal. Chem., 2006, 260(1-2), 77-81.
[http://dx.doi.org/10.1016/j.molcata.2006.06.043]
[37]
Davoodnia, A.; Zhiani, R.; Roshani, M.; Bakavoli, M.; Bashash, M. A new approach to the synthesis of fused pyrazoles: The synthesis of New Pyrazolo[4, 3-e][1, 2, 4] triazolo-[4, 3-a] pyrimidine-4 (5 H)-imines. Phosphorus Sulfur Silicon Relat. Elem., 2007, 182(6), 1219-1224.
[http://dx.doi.org/10.1080/10426500601160462]
[38]
Shamroukh, A.H.; Rashad, A.E.; Sayed, H.H. Synthesis of some pyrazolo [3, 4] pyrimidine derivatives for biological evaluation. Phosphorus Sulfur Silicon Relat. Elem., 2005, 180(10), 2347-2360.
[http://dx.doi.org/10.1080/104265090921074]
[39]
Shawali, A.S.; Hassaneen, H.M.; Shurrab, N.K. A new strategy for the synthesis of pyrazolo[4, 3-e][1, 2, 4]triazolo[4, 3-c] pyrimidines and pyrazolo[4, 3-e][1, 2, 4] triazolo[1, 5-c] pyrimidines. Tetrahedron, 2008, 64(45), 10339-10343.
[http://dx.doi.org/10.1016/j.tet.2008.08.082]
[40]
Avasthi, K.; Maurya, A.K. Facile Synthesis of 5-Substituted Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c] pyrimidines. Chem. Biol. Interact., 2015, 5(3), 188-195.
[41]
Rote, R.V.; Shelar, D.P.; Patil, S.R.; Jachak, M.N. A convenient synthesis of new pyrazolo[4, 3-d] pyrimidines and their fused heterocycles. J. Het. Chem., 2014, 51(3), 815-823.
[http://dx.doi.org/10.1002/jhet.2006]
[42]
Shurrab, N.K.; Alhendawi, H.; Kerrit, M.A. Synthesis of new 3, 7, 9-trisubstituted pyrazolo[4, 3-e][1, 2, 4]triazolo[4, 3-c] pyrimidines acyclo C-nucleosides via oxidative cyclisation. J. Chem. Res., 2018, 42(12), 601-603.
[http://dx.doi.org/10.3184/174751918X15414291150879]
[43]
Sheikhi-Mohammareh, S.; Shiri, A.; Bakavoli, M. Synthesis of new derivatives of pyrazolo[4, 3-e][1, 2, 4]triazolo[4, 3-c] pyrimidine. J. Chem. Res., 2015, 39(7), 403-406.
[http://dx.doi.org/10.3184/174751915X14357589569981]

Rights & Permissions Print Cite
Article Metrics
31
© 2024 Bentham Science Publishers | Privacy Policy